Johannes Andel

Landscape of HER2-low metastatic breast cancer (MBC): results from the Austrian AGMT_MBC-Registry

Simon Peter Gampenrieder, Gabriel Rinnerthaler, Christoph Tinchon et al. · Breast Cancer Research · 2021 · 154 citations · Full text

Medicine, Cancer Biology, Oncology +17

Preliminary safety and efficacy of first-line pertuzumab combined with trastuzumab and taxane therapy for HER2-positive locally recurrent or metastatic breast cancer (PERUSE)

Thomas Bachelot, Eva Ciruelos, Fabio Puglisi et al. · Annals of Oncology · 2019 · 113 citations · Full text

Medicine, Oncology, Pharmacology +17

Bevacizumab plus chemotherapy continued beyond first progression in patients with metastatic colorectal cancer previously treated with bevacizumab plus chemotherapy: ML18147 study KRAS subgroup findings

Stefan Kubicka, Richard Greil, Thierry André et al. · Annals of Oncology · 2013 · 103 citations · Full text

Medicine, Oncology, Pharmacotherapy +9

Maintenance treatment with the immunomodulator MGN1703, a Toll-like receptor 9 (TLR9) agonist, in patients with metastatic colorectal carcinoma and disease control after chemotherapy: a randomised, double-blind, placebo-controlled trial

Hans‐Joachim Schmoll, Burghardt Wittig, Dirk Arnold et al. · Journal of Cancer Research and Clinical Oncology · 2014 · 97 citations · Full text

Medicine, Oncology, Pharmacology +16

Olaptesed pegol (NOX-A12) with bendamustine and rituximab: a phase IIa study in patients with relapsed/refractory chronic lymphocytic leukemia

Michael Steurer, Marco Montillo, Lydia Scarfò et al. · Haematologica · 2019 · 91 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +17